» Articles » PMID: 1545386

The Effects of Chronic Buprenorphine Treatment on Cocaine and Food Self-administration by Rhesus Monkeys

Overview
Specialty Pharmacology
Date 1992 Mar 1
PMID 1545386
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The goal of this study was to determine if buprenorphine continues to reduce cocaine self-administration over long periods of treatment, or if tolerance develops to this effect. The effects of 30 to 120 days of buprenorphine treatment (0.32 mg/kg/day) on cocaine and food self-administration were examined in six rhesus monkeys. Saline control treatment was studied for 15 days before and after buprenorphine treatment. Intravenous cocaine (0.05 or 0.10 mg/kg) and food (1 g banana pellet) self-administration were maintained on a FR 4 (VR 16:S) schedule of reinforcement. Cocaine self-administration decreased significantly (P less than .0001) and remained 60 to 97% below saline treatment baseline levels (52 +/- 2 injections/day) throughout 120 days of buprenorphine treatment (P less than .01). After substitution of saline for buprenorphine, cocaine self-administration resumed and averaged between 21 (+/- 3.6) and 56 (+/- 6.5) injections per day over 20 days. Buprenorphine plasma levels averaged 18 (+/- 2.84) ng/ml (range 10.9-30 ng/ml) during buprenorphine treatment. Buprenorphine plasma levels usually decreased by 50% or more within 27 hr after the last buprenorphine dose. Low levels of buprenorphine (0.10-0.19 ng/ml) were measured for 30 to 74 days after abrupt termination of daily buprenorphine treatment. Food self-administration was initially reduced (P less than .01-.05), but tolerance to buprenorphine's suppression of food-maintained responding developed over 30 to 70 days of treatment. Food self-administration returned to and significantly exceeded (P less than .05-.01) saline treatment base-line levels, whereas cocaine self-administration remained significantly suppressed.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.

Ubaldi M, Cannella N, Borruto A, Petrella M, Micioni Di Bonaventura M, Soverchia L Int J Mol Sci. 2021; 22(23).

PMID: 34884757 PMC: 8657682. DOI: 10.3390/ijms222312956.


Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors.

Shen Q, Deng Y, Ciccocioppo R, Cannella N Front Psychiatry. 2017; 8:234.

PMID: 29180970 PMC: 5693905. DOI: 10.3389/fpsyt.2017.00234.


Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats.

de Guglielmo G, Matzeu A, Kononoff J, Mattioni J, Martin-Fardon R, George O J Pharmacol Exp Ther. 2017; 362(3):378-384.

PMID: 28645915 PMC: 5539589. DOI: 10.1124/jpet.117.241042.


Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.

Czoty P, Stoops W, Rush C Pharmacol Rev. 2016; 68(3):533-62.

PMID: 27255266 PMC: 4931869. DOI: 10.1124/pr.115.011668.


The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Aldrich J, Senadheera S, Ross N, Ganno M, Eans S, McLaughlin J J Nat Prod. 2013; 76(3):433-8.

PMID: 23327691 PMC: 3879116. DOI: 10.1021/np300697k.